Quinoline Derivative Stability via Silicic Acid and pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nitrogen-containing aromatic ring derivatives with a quinoline skeleton linked through an ether bond are unstable under humidified and heated storage conditions, leading to decomposition and gelation on the surface of pharmaceutical compositions, which delays the dissolution of active ingredients.
Innovation Solution
A pharmaceutical composition comprising 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide with a pH of 8 or more and/or silicic acid is used to reduce decomposition and inhibit gelation, ensuring stability and maintaining the quality of the active ingredient under humidified and heated storage conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nitrogen-containing aromatic ring derivatives with quinoline skeleton linked through ether bond are used as active ingredients, then angiogenic inhibition activity is improved, but stability under humidified and heated storage conditions deteriorates
Solution Approach 1:
The patent introduces a buffer substance as an intermediary component that mediates between the active ingredient and the storage environment. This buffer substance absorbs moisture and prevents direct contact between water and the ether bond of the quinoline derivative, thereby protecting the active ingredient from hydrolysis while maintaining the therapeutic activity.
Solution Approach 2:
The patent changes the storage parameters by controlling humidity levels and temperature to create favorable storage conditions. By maintaining low humidity and appropriate temperature ranges, the decomposition rate of the active ingredient is reduced, thereby improving stability without affecting the angiogenic inhibition activity.
2Reliability
If nitrogen-containing aromatic ring derivatives with quinoline skeleton linked through ether bond are used, then cancer cell growth inhibition is improved, but gelation on surface occurs during storage
Solution Approach 1:
The buffer substance acts as a protective intermediary that prevents gelation by absorbing moisture and creating a protective barrier. This intermediary component stops water from reaching the active ingredient surface, thereby preventing gelation while preserving the cancer cell growth inhibition activity.
Solution Approach 2:
The patent applies beforehand cushioning by incorporating moisture-absorbing materials into the formulation before storage. This preventive measure creates a protective environment that prevents gelation from occurring in the first place, rather than addressing gelation after it begins.
3Reliability
If nitrogen-containing aromatic ring derivatives with quinoline skeleton linked through ether bond are used, then vascular endothelial cell tube formation inhibition is improved, but decomposition occurs under humidified storage
Solution Approach 1:
The buffer substance serves as a protective intermediary that prevents direct interaction between water and the ether bond of the quinoline derivative. This intermediary absorbs moisture and creates a barrier, thereby preventing hydrolysis and decomposition while maintaining the vascular endothelial cell tube formation inhibition activity.
Solution Approach 2:
The patent creates an inert storage environment by controlling humidity levels and using moisture-absorbing materials. This inert environment prevents water from reaching the active ingredient, thereby preventing decomposition while preserving the anti-angiogenic activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively suppresses decomposition and prevents gelation, ensuring the stability and prolonged quality of the pharmaceutical composition by maintaining the integrity of the active ingredient during storage.
Implementation Method 1
silicic acid, salt thereof, or solvate of the foregoing
Implementation Method 2
a compound, a 5% (w/w) aqueous solution or suspension of which has a pH of 8 or more
Data Source
AI summary
A pharmaceutical composition comprising: an active ingredient consisting of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, salt thereof, or solvate of the foregoing; and (i) a compound, a 5% (w/w) aqueous solution or suspension of which has a pH of 8 or more, and/or (ii) silicic acid, salt thereof, or solvate of the foregoing is a highly stable pharmaceutical composition, wherein under humidified and heated storage conditions, the decomposition of said compound is sufficiently reduced, or the gelation on the surface of the pharmaceutical composition is sufficiently inhibited.